<DOC>
	<DOCNO>NCT00119769</DOCNO>
	<brief_summary>The purpose study investigate effect low-dose human growth hormone therapy immune status fat morphology .</brief_summary>
	<brief_title>The Effect Low-Dose Human Growth Hormone Therapy HIV Infected Patients</brief_title>
	<detailed_description>Following introduction highly active antiretroviral therapy ( HAART ) mid-nineties , improvement clinical course HIV lead dramatic reduction morbidity mortality . However , grow concern emergence increase number drug therapy failure , mainly cause rebound virus . This effect turn prompt respectively develop resistance fail compliance mainly due early late adverse reaction . These adverse reaction mainly consist number metabolic morphologic change , know HIV associate lipodystrophy syndrome ( HALS ) affect approximately 40 % HIV infect patient HAART . HALS characterize lipoatrophy extremity , gluteal facial region combine intraabdominal lipoaccumulation , `` buffalo hump '' lipoma . Thus , despite progress development new drug new target resistance profile need agent immune modulate property evident , way overcome problem resistance hopefully modify treatment regimen order reduce exposure late adverse reaction cause HAART . A number study address problem modulate immune response HIV infection . Results promise major obstacle seem adverse effect . In pre-HAART era high dose human growth hormone ( hGH ) therapy use HIV waste HAART era impact fat distribution HIV infect patient investigate base lipolytic property hGH . However high dosage hGH associate severe adverse effect limit usefulness daily clinical practice . One recent study demonstrate increment thymic mass rise number circulate na√Øve CD4 T cell upon treatment high dose hGH . Our group conduct 60 week pilot study daily injection 0.7 mg genotropin , demonstrate immune stimulate effect well increase limb fat/truncal fat ratio , without metabolic clinically recognizable side effect . Based finding plan perform randomize , double blind , prospective , interventional study include 50 HIV infect patient HAART , investigate effect low dose hGH immune status fat distribution .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lipodystrophy</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Male Caucasian race Age &gt; 21 year , &lt; 60 year HIV1 infection HAART treat &gt; 12 month HIVRNA &lt; 100 copies/ml CD4 count &gt; 200 Fasting plasma glucose &lt; 6.1 mM Stable weight BMI &gt; 28 kg/m2 BMI &lt; 18.5 kg/m2 Wasting AIDS define disease Severe chronic disease HIV Cancer , previous transplantation Previous AMI Diabetes Hormonal substitution therapy Lipid lower antidiabetic therapy within 3 month Abuse narcotic alcohol Major psychiatric disorder Adverse reaction towards Genotropin Calciumion &lt; 1.15 &gt; 1.35 mM Dvitamin &lt; 19 nM TSH &lt; 0.1 &gt; 10 mIU/l</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>HIV</keyword>
	<keyword>immune stimulation</keyword>
	<keyword>lipodystrophy</keyword>
	<keyword>growth hormone</keyword>
	<keyword>recombinant growth hormone</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>